The purpose of this study was to evaluate the effects of combined treatment with alendronate plus active or plain vitamin D on the vitamin D metabolism and bone turnover markers in patients with osteoporosis. Methods: We investigated 297 osteoporosis outpatients who were treated with Maxmarvil ® (alendronate 5 mg plus calcitriol 0.5 µg) daily or Fosamax Plus ® (alendronate 70 mg plus cholecalciferol 2,800 IU) weekly for 1 year. The serum levels of 25(OH)D, parathyroid hormone (PTH), calcium, phosphorus, osteocalcin and N-telopeptide were measured at baseline and after 3, 6, and 12 months of treatment.
INTRODUCTION
Osteoporosis has reached pandemic levels in elderly women and has markedly increased the incidence of bone fractures and mortality [1] . Pharmacological agents have been used for the prevention and treatment of osteoporosis, such as, bisphosphonates, raloxifene, and parathyroid hormone (PTH). Nevertheless, calcium and vitamin D are still widely regarded as first-line management strategies, either alone or in combination with other therapies, because of the high prevalence of vitamin D deficiency in elderly people [2] .
The major causes of vitamin D deficiency are a lack of exposure to the sun and a low dietary intake [3] . Vitamin D deficiency is usually defined as 25(OH) D level below 50 nmol/L (20 ng/mL), and according to this definition, vitamin D deficiency approaches 30%, even among postmenopausal women living in the developed countries regardless of latitude [4] .
The National Osteoporosis Foundation (NOF) recommends a daily vitamin D dose of 400-800 International Units (IU) for those aged < 50 and of 800-1,000 IU for those aged ≥ 50 [5] . However, in practice many osteoporosis patients do not take these recommended amounts. Vitamin D decreases the risk of osteoporotic fracture in postmenopausal women. However, the optimal form of vitamin D remains controversial, and although some studies have shown vitamin D analogs to be advantageous in some patients, these analogs are more expensive, and in the case of calcitriol, may be more likely to cause hypercalcemia than parent compound [6] .
Combining vitamin D with bisphosphonate increases calcium
http://www.enm-kes.org availability and stabilizes urinary calcium excretion. Furthermore, several authors have suggested that active vitamin D calcitriol and alfacalcidol [7] are interesting adjunctive partners for antiresorptive drugs like bisphosphonates [8] . This complementary effects might be due to suppressed bone turnover when administered with bisphosphonate, and the pleiotropic effects of vitamin D on calcium absorption, PTH reduction, bone mineralization and turnover, muscle function, and on the risk of falling.
The purpose of this study is to evaluate the effects of combined The follow-up data of the two treatment groups were analyzed with ANOVA repeated measure. The statistical differences between the two groups at baseline were examined with t-test. The μd is the statistical term which denotes the mean difference between groups.
RESULTS
The baseline characteristics of two groups were similar (Table 1) .
In both the Maxmarvil ® (alendronate and calcitriol) and Fosamax Plus ® (alendronate and cholecalciferol) group, there was no significant change in serum calcium, phosphorus and N-telopeptide levels during 3, 6, and 12 months, respectively.
In the Maxmarvil ® group, serum 25(OH)D showed no significant change. In the Fosamax Plus ® group, serum 25(OH)D increased by 77% from baseline at 3 months (μd = 9.87; ± 2.32 SE; P < 0.05) and remained significantly higher than baseline at 6 months (μd = 3.49; ± 0.86 SE; P < 0.05) and 12 months (μd = 10.47; ± 0.71 SE; P < 0.001) [9] (Fig. 1 ).
In the Maxmarvil ® group, serum PTH significantly decreased by 17% from baseline at 6 months (μd = -6.10; ± 0.85 SE; P < 0.05) and remained suppressed at 12 months (μd = -3.34; ± 0.95 SE; P = 0.54) without significance. However, in the Fosamax Plus ® group, serum PTH showed no significant change (Fig. 2 ).
In the Maxmarvil ® group, serum osteocalcin significantly decreased by 26% from baseline at 12 months (μd = -5.15; ± 0.35 SE; P < 0.05), and in the Fosamax Plus ® group, serum osteocalcin significantly decreased by 19% from baseline at 6 months (μd = -2.64; http://www.enm-kes.org ± 0.73 SE; P < 0.05) and remained suppressed at 12 months (μd = -2.99; ± 0.37 SE; P = 0.32) without significance (Fig. 3) .
DISCUSSION
Bisphosphonates act on osteoclasts to induce apoptosis, and thus, decrease bone resorption. Accordingly, bisphosphonate therapy increases bone mineral density and reduces fracture risk [10] .
In particular, alendronate is a potent inhibitor of bone resorption, and causes sustained reductions in the biochemical markers of bone remodeling and produces consistent dose-related increases in bone mineral density regardless of age and gender. Furthermore, these effects of alendronate have been associated with a substantially reduced risk of vertebral and non-vertebral fractures [11] .
In primary osteoporosis (postmenopausal or senile), the supplementation of vitamin D has a role because the interaction between 1,25(OH)2D3 and vitamin D receptor increases the efficiency of intestinal calcium and phosphorus absorption [12] . Primary vitamin D deficiency is caused by an inadequate supply of the precursors. ® group, serum 25(OH)D increased by 77% from baseline at 3 months (μd = 9.87; ± 2.32 SE; P < 0.05) and remained significantly higher than baseline at 6 months (μd = 3.49; ± 0.86 SE; P < 0.05) and 12 months (μd = 10.47; ± 0.71 SE; P < 0.001). *P < 0.05 vs. baseline value; † P < 0.05 vs. Fosamax Plus ® group. ® group, serum PTH decreased by 17% from baseline at 6 months (μd = -6.10; ± 0.85 SE; P < 0.05) and remained suppressed at 12 months (μd = -3.34; ± 0.95 SE; P = 0.54) without significance. In the Fosamax Plus ® group, serum PTH showed no significant change. *P < 0.05 vs. baseline value; † P < 0.05 vs. Fosamax Plus ® group. ® group, serum osteocalcin decreased by 26% from baseline at 12 months (μd = -5.15; ± 0.35 SE; P < 0.05). In the Fosamax Plus ® group, serum osteocalcin decreased by 19% from baseline at 6 months (μd = -2.64; ± 0.73 SE; P < 0.05) and remained suppressed at 12 months (μd = -2.99; ± 0.37 SE; P = 0.32) without significance. In both group, N-telopeptide showed no significant change. *P < 0.05 vs. baseline value. reported, whereas a reduction in alfacalcidol-induced hypercalcuria has been reported for this combination [16] . Richy et al. [17] conducted a meta-analysis study of the effects of plain vitamin D versus active vitamin D (alfacalcidol and calcitriol). All randomized, controlled, double-blinded trials that compared oral plain and active vitamin D to placebo were included. It was concluded that alfacalcidol and calcitriol possibly are more effective at preventing spinal bone loss in primary osteoporosis than plain vitamin D [17] . In the present study, we compared the effects of calcitriol versus cholecalciferol with combination of alendronate in Korean osteoporotic patients. Serum vitamin D status and bone turnover markers were followed-up for 12 months (relatively long duration) in a real world clinical practice setting. The limitations of our study are that was based on a retrospective chart review, subjects were not randomized, the sample size was relatively small, patient compliance was not checked, and some data were missing.
In conclusion, alendronate 5 mg and calcitriol 0. 
